ArticlePharmaceutical research2026
Osmolyte-Based Formulations for Enhanced Thermal Stability of mRNA Drug Substance: A Systematic Screening and Optimization Study.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStability of messenger RNA (mRNA) is a critical factor in the development and storage of mRNA-based vaccines. In this study, we systematically examine the effects of addition of various osmolytes (and their combinations) on mRNA integrity during long-term storage and under thermal stress.
methodsEleven osmolytes, belonging to subclasses of amino acids and derivatives (ectoine, methionine, L-cysteine, valine), polyols and sugars (sorbitol, trehalose and mannose), nucleosides (uridine), and vitamins and cofactors (nicotinamide and citric acid) have been examined by themselves as well in binary and ternary combinations. Their protective capacity has been evaluated. A concentration curve was developed where we assessed 0-30% weight/volume of the osmolytes in the mRNA vaccine formulations and analyzed the thermostability for 5-14 days in 40°C and 2.5 months at 4°C.
resultsAn optimized formulation of 80:20 taurine to uridine showed robust mRNA protection across 15-30% w/v concentrations (densitometric indices 0.833-0.875, p < 0.001) with exceptional stability at 1% w/v (0.966 ± 0.061) after 5 days at 40°C, while the ternary taurine-uridine-sorbitol system achieved peak performance at 5% w/v (0.917 ± 0.036). This established a concentration-dependent design principle for thermostable mRNA formulations with > tenfold improvement over untreated controls under accelerated thermal stress conditions.
conclusionsOur results revealed that the effectiveness of each component depended not only on its identity but also on the composition of the formulation. Ternary mixtures did not always outperform binary systems. Our work demonstrates that osmolytes offer significant potential towards improving the shelf life and accessibility of mRNA vaccines.
Indexed as
Identifiers
42414834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.